Search

Your search keyword '"Chakaya J"' showing total 25 results
Start Over Author "Chakaya J" Publisher international union against tuberculosis and lung disease
25 results on '"Chakaya J"'

1. Disability, comorbidities and risk determinants at end of TB treatment in Kenya, Uganda, Zambia and Zimbabwe

Author

Adakun, S.A., primary, Banda, F.M., additional, Bloom, A., additional, Bochnowicz, M., additional, Chakaya, J., additional, Chansa, A., additional, Chiguvare, H., additional, Chimzizi, R., additional, Colvin, C., additional, Dongo, J.P., additional, Durena, A., additional, Duri, C., additional, Edmund, R., additional, Harries, A.D., additional, Kathure, I., additional, Kavenga, F.N., additional, Lin, Y., additional, Luzze, H., additional, Mbithi, I., additional, Mputu, M., additional, Mubanga, A., additional, Nair, D., additional, Ngwenya, M., additional, Okotu, B., additional, Owiti, P., additional, Owuor, A., additional, Thekkur, P., additional, Timire, C., additional, Turyahabwe, S., additional, Tweyongyere, E., additional, YaDiul, M., additional, Zachariah, R., additional, and Zimba, K., additional

Published
2024
Full Text
View/download PDF

2. Applying ‘timeliness’ to the screening and prevention of TB in household contacts of pulmonary TB patients

Author

Harries, A. D., primary, Nair, D., additional, Thekkur, P., additional, Ananthakrishnan, R., additional, Thiagesan, R., additional, Chakaya, J. M., additional, Mbithi, I., additional, Jamil, B., additional, Fatima, R., additional, Khogali, M., additional, Zachariah, R., additional, Berger, S. Dar, additional, Satyanarayana, S., additional, Kumar, A. M. V., additional, Bochner, A. F., additional, and McClelland, A., additional

Published
2024
Full Text
View/download PDF

3. Clinical standards for diagnosis, treatment and prevention of post-COVID-19 lung disease

Author

Visca, D., primary, Centis, R., additional, Pontali, E., additional, Zampogna, E., additional, Russell, A.-M., additional, Migliori, G. B., additional, Andrejak, C., additional, Aro, M., additional, Bayram, H., additional, Berkani, K., additional, Bruchfeld, J., additional, Chakaya, J. M., additional, Chorostowska-Wynimko, J., additional, Crestani, B., additional, Dalcolmo, M. P., additional, D’Ambrosio, L., additional, Dinh-Xuan, A-T., additional, Duong-Quy, S., additional, Fernandes, C., additional, García-García, J.-M., additional, de Melo Kawassaki, A, additional, Carrozzi, L., additional, Martinez-Garcia, M. A., additional, Martins, P. Carreiro, additional, Mirsaeidi, M., additional, Mohammad, Y., additional, Naidoo, R. N., additional, Neuparth, N., additional, Sese, L., additional, Silva, D. R., additional, Solovic, I., additional, Sooronbaev, T. M., additional, Spanevello, A., additional, Sverzellati, N., additional, Tanno, L., additional, Tiberi, S., additional, Vasankari, T., additional, Vasarmidi, E., additional, Vitacca, M., additional, and Annesi-Maesano, I., additional

Published
2023
Full Text
View/download PDF

4. Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries

Author

Stolbrink, M, Chinouya, MJ, Jayasooriya, S, Nightingale, R, Evans-Hill, L, Allan, K, Allen, H, Balen, J, Beacon, T, Bissell, K, Chakaya, J, Chiang, C-Y, Cohen, M, Devereux, G, El Sony, A, Halpin, DMG, Hurst, Kiprop, C, Lawson, A, Macé, C, Makhanu, A, Makokha, P, Masekela, R, Meme, H, Khoo, EM, Nantanda, R, Pasternak, S, Perrin, C, Reddel, H, Rylance, S, Schweikert, P, Were, C, Williams, S, Winders, T, Yorgancioglu, A, Marks, GB, Mortimer, K, Jayasooriya, S [0000-0002-1147-5744], Balen, J [0000-0002-4736-8465], Hurst, J R [0000-0002-7246-6040], Williams, S [0000-0002-0527-2254], and Apollo - University of Cambridge Repository

Subjects
Pulmonary and Respiratory Medicine, History, Infectious Diseases, Polymers and Plastics, Income, Humans, Business and International Management, Global Health, Respiration Disorders, Developing Countries, Poverty, Industrial and Manufacturing Engineering
Abstract

Funder: Medical Research Council, BACKGROUND: Access to affordable inhaled medicines for chronic respiratory diseases (CRDs) is severely limited in low- and middle-income countries (LMICs), causing avoidable morbidity and mortality. The International Union Against Tuberculosis and Lung Disease convened a stakeholder meeting on this topic in February 2022.METHODS: Focused group discussions were informed by literature and presentations summarising experiences of obtaining inhaled medicines in LMICs. The virtual meeting was moderated using a topic guide around barriers and solutions to improve access. The thematic framework approach was used for analysis.RESULTS: A total of 58 key stakeholders, including patients, healthcare practitioners, members of national and international organisations, industry and WHO representatives attended the meeting. There were 20 pre-meeting material submissions. The main barriers identified were 1) low awareness of CRDs; 2) limited data on CRD burden and treatments in LMICs; 3) ineffective procurement and distribution networks; and 4) poor communication of the needs of people with CRDs. Solutions discussed were 1) generation of data to inform policy and practice; 2) capacity building; 3) improved procurement mechanisms; 4) strengthened advocacy practices; and 5) a World Health Assembly Resolution.CONCLUSION: There are opportunities to achieve improved access to affordable, quality-assured inhaled medicines in LMICs through coordinated, multi-stakeholder, collaborative efforts.

Published
2022

5. A systematic review of the costs of diagnosis for multidrug-resistant/extensively drug-resistant TB in different settings

Author

Saderi, L., primary, Cabibbe, A. M., additional, Puci, M., additional, Di Lorenzo, B., additional, Centis, R., additional, Pontali, E., additional, van den Boom, M., additional, Chakaya, J. M., additional, D´Ambrosio, L., additional, Denholm, J. T., additional, Ferrara, G., additional, Silva, D. R., additional, Solovic, I., additional, Spanevello, A., additional, Visca, D., additional, Sotgiu, G., additional, and Migliori, G. B., additional

Published
2023
Full Text
View/download PDF

7. Clinical standards for drug-susceptible pulmonary TB

Author

Akkerman, O. W., primary, Duarte, R., additional, Tiberi, S., additional, Schaaf, H. S., additional, Lange, C., additional, Alffenaar, J. W. C., additional, Denholm, J., additional, Carvalho, A. C. C., additional, Bolhuis, M. S., additional, Borisov, S., additional, Bruchfeld, J., additional, Cabibbe, A. M., additional, Caminero, J. A., additional, Carvalho, I., additional, Chakaya, J., additional, Centis, R., additional, Dalcomo, M. P., additional, D´Ambrosio, L., additional, Dedicoat, M., additional, Dheda, K., additional, Dooley, K. E., additional, Furin, J., additional, García-García, J-M., additional, van Hest, N. A. H., additional, de Jong, B. C., additional, Kurhasani, X., additional, Märtson, A. G., additional, Mpagama, S., additional, Torrico, M. Munoz, additional, Nunes, E., additional, Ong, C. W. M., additional, Palmero, D. J., additional, Ruslami, R., additional, Saktiawati, A. M. I., additional, Semuto, C., additional, Silva, D. R., additional, Singla, R., additional, Solovic, I., additional, Srivastava, S., additional, de Steenwinkel, J. E. M., additional, Story, A., additional, Sturkenboom, M. G. G., additional, Tadolini, M., additional, Udwadia, Z. F., additional, Verhage, A. R., additional, Zellweger, J. P., additional, and Migliori, G. B., additional

Published
2022
Full Text
View/download PDF

8. Clinical standards for the dosing and management of TB drugs

Author

Alffenaar, J. W. C., primary, Stocker, S. L., additional, Forsman, L. Davies, additional, Garcia-Prats, A., additional, Heysell, S. K., additional, Aarnoutse, R. E., additional, Akkerman, O. W., additional, Aleksa, A., additional, van Altena, R., additional, de Oñata, W. Arrazola, additional, Bhavani, P. K., additional, van‘t Boveneind-Vrubleuskaya, N., additional, Carvalho, A. C. C., additional, Centis, R., additional, Chakaya, J. M., additional, Cirillo, D. M., additional, Cho, J. G., additional, D´Ambrosio, L., additional, Dalcolmo, M. P., additional, Denti, P., additional, Dheda, K., additional, Fox, G. J., additional, Hesseling, A. C., additional, Kim, H. Y., additional, Köser, C. U., additional, Marais, B. J., additional, Margineanu, I., additional, Märtson, A. G., additional, Torrico, M. Munoz, additional, Nataprawira, H. M., additional, Ong, C. W. M., additional, Otto-Knapp, R., additional, Peloquin, C. A., additional, Silva, D. R., additional, Ruslami, R., additional, Santoso, P., additional, Savic, R. M., additional, Singla, R., additional, Svensson, E. M., additional, Skrahina, A., additional, van Soolingen, D., additional, Srivastava, S., additional, Tadolini, M., additional, Tiberi, S., additional, Thomas, T. A., additional, Udwadia, Z. F., additional, Vu, D. H., additional, Zhang, W., additional, Mpagama, S. G., additional, Schön, T., additional, and Migliori, G. B., additional

Published
2022
Full Text
View/download PDF

9. Clinical standards for the dosing and management of TB drugs

Author

Alffenaar, J. W. C., Stocker, S. L., Forsman, L. Davies, Garcia-Prats, A., Heysell, S. K., Aarnoutse, R. E., Akkerman, O. W., Aleksa, A., van Altena, R., de Onata, W. Arrazola, Bhavani, P. K., Van't Boveneind-Vrubleuskaya, N., Carvalho, A. C. C., Centis, R., Chakaya, J. M., Cirillo, D. M., Cho, J. G., Ambrosio, L. D., Dalcolmo, M. P., Denti, P., Dheda, K., Fox, G. J., Hesseling, A. C., Kim, H. Y., Koser, C. U., Marais, B. J., Margineanu, I, Martson, A. G., Torrico, M. Munoz, Nataprawira, H. M., Ong, C. W. M., Otto-Knapp, R., Peloquin, C. A., Silva, D. R., Ruslami, R., Santoso, P., Savic, R. M., Singla, R., Svensson, Elin, Skrahina, A., van Soolingen, D., Srivastava, S., Tadolini, M., Tiberi, S., Thomas, T. A., Udwadia, Z. F., Vu, D. H., Zhang, W., Mpagama, S. G., Schon, T., Migliori, G. B., Alffenaar, J. W. C., Stocker, S. L., Forsman, L. Davies, Garcia-Prats, A., Heysell, S. K., Aarnoutse, R. E., Akkerman, O. W., Aleksa, A., van Altena, R., de Onata, W. Arrazola, Bhavani, P. K., Van't Boveneind-Vrubleuskaya, N., Carvalho, A. C. C., Centis, R., Chakaya, J. M., Cirillo, D. M., Cho, J. G., Ambrosio, L. D., Dalcolmo, M. P., Denti, P., Dheda, K., Fox, G. J., Hesseling, A. C., Kim, H. Y., Koser, C. U., Marais, B. J., Margineanu, I, Martson, A. G., Torrico, M. Munoz, Nataprawira, H. M., Ong, C. W. M., Otto-Knapp, R., Peloquin, C. A., Silva, D. R., Ruslami, R., Santoso, P., Savic, R. M., Singla, R., Svensson, Elin, Skrahina, A., van Soolingen, D., Srivastava, S., Tadolini, M., Tiberi, S., Thomas, T. A., Udwadia, Z. F., Vu, D. H., Zhang, W., Mpagama, S. G., Schon, T., and Migliori, G. B.

Abstract

Background: Optimal drug dosing is important to ensure adequate response to treatment, prevent development of drug resistance and reduce drug toxicity. The aim of these clinical standards is to provide guidance on 'best practice' for dosing and management of TB drugs. Methods: A panel of 57 global experts in the fields of microbiology, pharmacology and TB care were identified; 51 participated in a Delphi process. A 5-point Likert scale was used to score draft standards. The final document represents the broad consensus and was approved by all participants. Results: Six clinical standards were defined: Standard 1, defining the most appropriate initial dose for TB treatment; Standard 2, identifying patients who may be at risk of sub-optimal drug exposure; Standard 3, identifying patients at risk of developing drug-related toxicity and how best to manage this risk; Standard 4, identifying patients who can benefit from therapeutic drug monitoring (TDM); Standard 5, highlighting education and counselling that should be provided to people initiating TB treatment; and Standard 6, providing essential education for healthcare professionals. In addition, consensus research priorities were identified. Conclusion: This is the first consensus-based Clinical Standards for the dosing and management of TB drugs to guide clinicians and programme managers in planning and implementation of locally appropriate measures for optimal person-centred treatment to improve patient care.

Published
2022
Full Text
View/download PDF

10. Clinical standards for the assessment, management and rehabilitation of post-TB lung disease

Author

Migliori, G. B., primary, Marx, F. M., additional, Ambrosino, N., additional, Zampogna, E., additional, Schaaf, H. S., additional, van der Zalm, M. M., additional, Allwood, B., additional, Byrne, A. L., additional, Mortimer, K., additional, Wallis, R. S., additional, Fox, G. J., additional, Leung, C. C., additional, Chakaya, J. M., additional, Seaworth, B., additional, Rachow, A., additional, Marais, B. J., additional, Furin, J., additional, Akkerman, O. W., additional, Al Yaquobi, F., additional, Amaral, A. F. S., additional, Borisov, S., additional, Caminero, J. A., additional, Carvalho, A. C. C., additional, Chesov, D., additional, Codecasa, L. R., additional, Teixeira, R. C., additional, Dalcolmo, M. P., additional, Datta, S., additional, Dinh-Xuan, A-T., additional, Duarte, R., additional, Evans, C. A., additional, García-García, J-M., additional, Günther, G., additional, Hoddinott, G., additional, Huddart, S., additional, Ivanova, O., additional, Laniado-Laborín, R., additional, Manga, S., additional, Manika, K., additional, Mariandyshev, A., additional, Mello, F. C. Q., additional, Mpagama, S. G., additional, Muñoz-Torrico, M., additional, Nahid, P., additional, Ong, C. W. M., additional, Palmero, D. J., additional, Piubello, A., additional, Pontali, E., additional, Silva, D. R., additional, Singla, R., additional, Spanevello, A., additional, Tiberi, S., additional, Udwadia, Z. F., additional, Vitacca, M., additional, Centis, R., additional, D´Ambrosio, L., additional, Sotgiu, G., additional, Lange, C., additional, and Visca, D., additional

Published
2021
Full Text
View/download PDF

15. COVID-19 in Africa: preparing for the storm

Author

Chakaya, J., primary, Binegdie, A., additional, Irungu, A., additional, Pearson, B., additional, Gray, D., additional, Zar, H. J., additional, Schewitz, I., additional, Kagima, J., additional, Mortimer, K., additional, Ozoh, O. B., additional, Masekela, R., additional, Gordon, S. B., additional, Worodria, W., additional, and Aluoch, J., additional

Published
2020
Full Text
View/download PDF

20. Evaluation of the FluoreslenS and fluorescence microscopy blinded rechecking trial, Nairobi, Kenya

Author

Torrea, G., Chakaya, J., Mayabi, M., and Van Deun, A.

Subjects
Fluorescence microscopy, Staining, User-friendliness, Bacterial diseases, Africa, East, Feasibility, Evaluation studies, Kenya, Sensitivity, Ziehl-Neelsen smear, Auramine, Specificity, Tuberculosis, Case detection
Abstract

SETTING: Three busy laboratories in Nairobi, Kenya. OBJECTIVES: To determine the performance of an affordable fluorescence system (FluoreslenS) for tuberculosis microscopy, and to test an auramine-smear rechecking system. DESIGN: Alternating routine use of Ziehl-Neelsen (ZN) and fluorescence microscopy (FM) was performed to compare detection and errors found while rechecking. RESULTS: Overall, 19.5% of 25,250 ZN and 23% of 21,104 FM smears were positive (P < 10(-3)). The proportional increment of FM over ZN was 18% (range -6%-29%), with one centre detecting fewer positives (non-significant, NS). The average error frequencies were comparable (1.8% vs. 2.6% false-negative and 0.2% vs. 0.4% high false-positive for ZN and FM, respectively, NS). The superior performance of controllers and the overall equal ZN/FM quality in the laboratories could be demonstrated only after converting error percentages to relative sensitivity (RS). CONCLUSIONS: FM with the FluoreslenS system considerably improved sensitivity without loss of specificity in two of the busy routine laboratories, but the system is not sufficiently practical or user-friendly. Rechecking by FM can be done using guidelines for ZN smears, provided that routine ZN confirmation of positives is omitted. Calculation of RS allows an objective comparison of microscopy quality, independent of the variable prevalence of positives and sample size.

Published
2008

25. Timeliness metrics for screening and preventing TB in household contacts of pulmonary TB patients in Kenya.

Author

Nair D, Thekkur P, Mbithi I, Khogali M, Zachariah R, Dar Berger S, Satyanarayana S, Kumar AMV, Kathure I, Mwangi J, Bochner AF, McClelland A, Chakaya JM, and Harries AD

Abstract

Background: The study assessed whether a "7-1-7" timeliness metric for screening and TB preventive therapy (TPT) could be implemented for household contacts (HHCs) of index patients with bacteriologically confirmed pulmonary TB under routine programmatic settings in Kenya., Methods: A longitudinal cohort study conducted among index patients and their HHCs in 12 health facilities, Kiambu County, Kenya., Results: Between January and June 2023, 95% of 508 index patients had their HHCs line-listed within 7 days of initiating anti-TB treatment ("First 7"). In 68% of 1,115 HHCs, screening outcomes were ascertained within 1 day of line-listing ("Next 1"). In 65% of 1,105 HHCs eligible for further evaluation, anti-TB treatment, TPT or a decision for no drugs was made within 7 days of screening ("Second 7"). Altogether, 62% of screened HHCs started TPT during the "7-1-7" period compared with 58% in a historical cohort. Main barriers to TPT uptake were HHCs not consulting clinicians, HHCs being unwilling to initiate TPT and drug shortages. Healthcare workers felt that a timeliness metric was valuable for streamlining HHC management and proposed "3-5-7" as a workable alternative., Conclusions: The national TB programme must generate awareness about TPT, ensure uninterrupted drug supplies and assess whether the "3-5-7" metric can be operationalised., Competing Interests: Conflicts of interest: none declared., (© 2024 The Authors.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results